New clinical trial data show children with MS may benefit as much from treatment with Ocrevus as Gilenya – and for some outcomes, more.
A 24-parameter spectral flow cytometry panel was developed to monitor immune receptor expression in MS patients, aiding personalized treatment approaches. The panel detects 12 treatment-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback